NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
NanoViricides, Inc. (NYSE American: NNVC) emphasized the growing need for broad-spectrum antiviral treatments after a recent Andes hantavirus incident aboard a cruise ship, highlighting its clinical-stage candidate NV-387 as a potential platform to address emerging viral threats. The company announced that NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers and shown effectiveness in animal models against multiple viral lung infections, including coronaviruses, RSV, influenza, monkeypox, and measles. This development positions NV-387 as a promising therapeutic for a range of pathogenic viruses.
The Andes hantavirus case on a cruise ship serves as a reminder of the unpredictable nature of viral outbreaks and the limitations of pathogen-specific treatments. NanoViricides is advancing NV-387 as a broad-spectrum antiviral designed to target diverse viral families, potentially offering a faster response to novel threats. The drug candidate has demonstrated efficacy in animal models for monkeypox, smallpox, and measles, in addition to respiratory viruses, according to the company.
NV-387 is a unique nanomaterial-based antiviral that the company plans to develop for RSV, COVID-19, Long COVID, influenza, and other respiratory infections. It successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, and NanoViricides is now focusing on advancing it into Phase II trials. The company's other advanced candidate, NV-HHV-1, targets herpesvirus infections including HSV-1, HSV-2, VZV shingles, and chickenpox.
The recent hantavirus incident underscores the importance of stockpiling broad-spectrum antivirals for public health preparedness. NanoViricides' platform could play a role in mitigating future outbreaks, as it aims to provide a therapeutic option that works across multiple viral families. The company noted that NV-387's mechanism of action targets viral entry and fusion, making it potentially effective against emerging variants.
For more information on NanoViricides, visit www.nanoviricides.com. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. The full press release can be viewed at https://ibn.fm/OYkof.